Xeloda 500 mg Alternative – Capixet (Capecitabine) 500 mg Tablet | Everest Pharmaceuticals
Capixet 500 mg (Capecitabine) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xeloda (Roche). It belongs to the oral fluoropyrimidine chemotherapy class and is used in selected colorectal, breast and other cancer regimens.
Active ingredient: Capecitabine
Strength: 500 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Product Overview
Capixet 500 mg Tablet by Everest Pharmaceuticals Ltd., Bangladesh contains Capecitabine. It is listed here as a same-ingredient branded option for people researching Xeloda, a reference brand associated with Roche. Capixet and Xeloda must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 500 mg strength.
Capixet vs. Xeloda – Originator / Reference Brand Comparison
Xeloda is a widely recognized reference brand for Capecitabine associated with Roche. Capixet is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Capixet is manufactured by Roche, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.
Composition and Active Ingredient
Active ingredient: Capecitabine
Strength: 500 mg
Dosage form: Tablet
Pharmacological class: oral fluoropyrimidine chemotherapy
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.
Therapeutic Uses and Indications
Capecitabine is used in selected colorectal, breast and other cancer regimens. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.
Mechanism of Action – How Capecitabine Works
Capecitabine is a oral fluoropyrimidine chemotherapy. In general, it is converted into fluorouracil, interfering with DNA synthesis. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.
Dosage and Administration
The product contains 500 mg per tablet; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.
Contraindications
Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.
Warnings and Precautions
Important precautions for Capecitabine include: hand-foot syndrome, diarrhea and potentially severe toxicity with DPD deficiency. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.
Possible Side Effects
The adverse-effect profile of Capecitabine varies by indication and combination regimen. Relevant potential adverse effects and serious risks include hand-foot syndrome, diarrhea and potentially severe toxicity with DPD deficiency. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.
Drug Interactions
Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Capecitabine. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.
Pregnancy, Fertility and Breastfeeding
Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Capecitabine without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.
Storage and Handling
Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.
Why Is Capixet Listed as an Alternative to Xeloda?
This listing helps customers identify an Everest Pharmaceuticals product containing Capecitabine while researching Xeloda. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.
Manufacturer Information
Listed brand: Capixet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Xeloda
Reference company: Roche
Generic ingredient: Capecitabine
Strength: 500 mg
Dosage form: Tablet
Therapeutic class: oral fluoropyrimidine chemotherapy
Frequently Asked Questions
What is Capixet 500 mg?
It is an Everest Pharmaceuticals tablet containing Capecitabine 500 mg.
Is Capixet the same as Xeloda?
They are presented as brands associated with Capecitabine, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.
What is Capecitabine used for?
Capecitabine is used in selected colorectal, breast and other cancer regimens, subject to the applicable label and clinical assessment.
How does Capecitabine work?
It is converted into fluorouracil, interfering with DNA synthesis.
Can I switch strengths or brands myself?
No. A licensed prescriber or pharmacist must assess any substitution.
Is a prescription needed?
Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.
Important Medical Disclaimer
This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.
| Generic Name | Capecitabine |
|---|---|
| Strength | 500 mg |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack Size | 14 tablets |
Related products
Alecensa 150 mg Alternative – Alecnib (Alectinib) 150 mg Capsule | Everest Pharmaceuticals
Alecnib 150 mg (Alectinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Alecensa (Roche / Genentech). It belongs to the ALK inhibitor class and is used in appropriately tested ALK-positive non-small cell lung cancer.
Active ingredient: Alectinib
Strength: 150 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Cometriq 20 mg Alternative – Caboxen (Cabozantinib) 20 mg Capsule | Everest Pharmaceuticals
Caboxen 20 mg (Cabozantinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Cometriq (Exelixis). It belongs to the multikinase inhibitor class and is used in selected medullary thyroid cancer settings for capsule formulations; other cabozantinib formulations have different approved uses.
Active ingredient: Cabozantinib
Strength: 20 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Kisqali 200 mg Alternative – Riboxen (Ribociclib) 200 mg Tablet | Everest Pharmaceuticals
Riboxen 200 mg (Ribociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Kisqali (Novartis). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Ribociclib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lumakras / Lumykras 120 mg Alternative – Sotoxen (Sotorasib) 120 mg Tablet | Everest Pharmaceuticals
Sotoxen 120 mg (Sotorasib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lumakras / Lumykras (Amgen). It belongs to the KRAS G12C inhibitor class and is used in selected KRAS G12C-mutated non-small cell lung cancer.
Active ingredient: Sotorasib
Strength: 120 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lynparza 150 mg Alternative – Olanib (Olaparib) 150 mg Tablet | Everest Pharmaceuticals
Olanib 150 mg (Olaparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lynparza (AstraZeneca / MSD). It belongs to the PARP inhibitor class and is used in selected ovarian, breast, pancreatic and prostate cancers.
Active ingredient: Olaparib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Nexavar 200 mg Alternative – Hepanib (Sorafenib) 200 mg Tablet | Everest Pharmaceuticals
Hepanib 200 mg (Sorafenib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Nexavar (Bayer). It belongs to the multikinase inhibitor class and is used in selected liver, kidney and thyroid cancers.
Active ingredient: Sorafenib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Zejula 100 mg Alternative – Niranib (Niraparib) 100 mg Capsule | Everest Pharmaceuticals
Niranib 100 mg (Niraparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zejula (GSK). It belongs to the PARP inhibitor class and is used in selected ovarian cancer maintenance treatment settings.
Active ingredient: Niraparib
Strength: 100 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Zytiga 250 mg Alternative – Abiraxen (Abiraterone acetate) 250 mg Tablet | Everest Pharmaceuticals
Abiraxen 250 mg (Abiraterone acetate) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zytiga (Janssen). It belongs to the androgen biosynthesis inhibitor class and is used in selected advanced prostate cancer regimens with corticosteroid therapy.
Active ingredient: Abiraterone acetate
Strength: 250 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.